Bragar, Eagel & Squire, P.C. Is Investigating the Officers and Directors of Northwest Biotherapeutics on Behalf of Stockholders
November 02 2015 - 6:53PM
Business Wire
Bragar Eagel & Squire, P.C. is investigating potential
claims on behalf of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)
investors concerning whether the company’s officers and board of
directors violated their fiduciary duties.
On June 19, 2014 shares of the Company fell $2.06, or 22.97%,
during intraday trading after a report featured on TheStreet.com
stated, “The prestigious MD Anderson Cancer Center issued a stern
rebuke to Northwest Biotherapeutics (NWBO) for making promotional,
unjustified claims about results from an ongoing clinical trial of
an experimental cancer vaccine known as DCVax-Direct.” MD Anderson
Cancer Center is running the DCVax-Direct clinical trial with
funding from Northwest Biotherapeutics. According to the report,
investigators at MD Anderson, one of several sites conducting the
study, have not yet been able to analyze data collected because
patients are still being enrolled and treated in the study.
If you are a Northwest Biotherapeutics, Inc. stockholder and
have information that could assist in this investigation, please
contact J. Brandon Walker, Esq. by email at
investigations@bespc.com, or telephone at (212) 355-4648, or by
filling out this contact form. There is no cost or obligation to
you.
Bragar Eagel & Squire, P.C. is a New York-based law firm
concentrating in commercial and securities litigation. For
additional information, please go to www.bespc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151102006957/en/
Bragar Eagel & Squire, P.C.J. Brandon Walker, Esq.,
212-355-4648investigations@bespc.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024